Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pachner, A. R.
Right arrow Articles by Pak, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pachner, A. R.
Right arrow Articles by Pak, E.
Related Collections
Right arrow All Immunology
Right arrow Autoimmune diseases
Right arrow Parasitic infections
Right arrow Gene expression studies
NEUROLOGY 2006;66:444-446
© 2006 American Academy of Neurology
Brief Communications

Multiplex analysis of expression of three IFNß-induced genes in antibody-positive MS patients

Andrew R. Pachner, MD, Kavitha Narayan, MS and Elena Pak, MS

From the University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, NJ.

Address correspondence and reprint requests to Dr. Andrew R. Pachner, Department of Neurology and Neurosciences, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103; e-mail: pachner{at}umdnj.edu

Some interferon beta (IFNß)–treated patients with multiple sclerosis develop antibody-mediated decreased bioactivity with resultant loss of therapeutic effect. The authors developed real-time multiplex reverse transcriptase PCR to measure expression of three IFNß-inducible genes to directly assess IFNß bioactivity in patients with neutralizing antibodies (NAbs). The three genes responded in tandem. Correlation of NAb level with bioactivity at low/moderate NAb levels was poor, indicating that for such patients, direct measurement of IFNß bioactivity is most reliable.

The study was funded by grants from the National Multiple Sclerosis Society (RG3402), Biogen Idec, Pfizer/Serono, and Berlex.

Disclosure: Dr. Pachner has received honoraria from Berlex, Serono, Biogen, and Teva and has received grant support for research from Berlex, Serono, and Biogen. Ms. Narayan and Ms. Pak report no conflicts of interest.

Received July 26, 2005. Accepted in final form October 19, 2005.




This article has been cited by other articles:


Home page
 NeurologyHome page
A. R. Pachner, D. Cadavid, L. Wolansky, and J. Skurnick
Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study
Neurology, November 3, 2009; 73(18): 1485 - 1492.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. R. Pachner, J. D. Warth, A. Pace, S. Goelz, and On behalf of the INSIGHT investigators
Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study
Neurology, November 3, 2009; 73(18): 1493 - 1500.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. Hesse, F. Sellebjerg, and P. S. Sorensen
Absence of MxA induction by interferon {beta} in patients with MS reflects complete loss of bioactivity
Neurology, August 4, 2009; 73(5): 372 - 377.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in Neurological DisordersHome page
P. Soelberg Sorensen
Review: Neutralizing antibodies against interferon-beta
Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 125 - 141.
[Abstract] [PDF]

Home page
 Mult SclerHome page
F Sellebjerg, P Datta, J Larsen, K Rieneck, I Alsing, A Oturai, A Svejgaard, P Soelberg Sorensen, and L. Ryder
Gene expression analysis of interferon-{beta} treatment in multiple sclerosis
Multiple Sclerosis, June 1, 2008; 14(5): 615 - 621.
[Abstract] [PDF]

Home page
 NeurologyHome page
S. Malucchi, F. Gilli, M. Caldano, F. Marnetto, P. Valentino, L. Granieri, A. Sala, M. Capobianco, and A. Bertolotto
Predictive markers for response to interferon therapy in patients with multiple sclerosis
Neurology, March 25, 2008; 70(13_Part_2): 1119 - 1127.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
A.R. Pachner
Neutralizing anti-IFN{beta} antibodies: clarity and confusion
Multiple Sclerosis, November 1, 2007; 13(9): 1081 - 1082.
[PDF]

Home page
 NeurologyHome page
A. R. Pachner and D. S. Goodin
Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurology, October 9, 2007; 69(15): 1555 - 1556.
[Full Text] [PDF]

Home page
 Mult SclerHome page
A.R. Pachner
Real-time TaqMan assay for myxovirus resistance protein (MxA) mRNA: a robust marker of interferon beta bioactivity in patients with multiple sclerosis
Multiple Sclerosis, May 1, 2007; 13(1_suppl): 49 - 52.
[Abstract] [PDF]

Home page
 NeurologyHome page
L. A. Hoffmann, M. Krumbholz, H. Faber, T. Kuempfel, M. Starck, W. Pollmann, E. Meinl, and R. Hohlfeld
Multiple sclerosis: Relating MxA transcription to anti-interferon-{beta}-neutralizing antibodies
Neurology, March 20, 2007; 68(12): 958 - 959.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.